Lee, J. K. et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. npj Precis. Oncol. 6, 91 (2022).
Google ScholarÂ
Salem, M. E. et al. Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS-mutated cancers. JCO Precis. Oncol. 6, e2100245 (2022).
Google ScholarÂ
Wu, L. et al. Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China. J. Cancer Res. Clin. Oncol. 151, 94 (2025).
Google ScholarÂ
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Google ScholarÂ
Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153–168 (2020).
Google ScholarÂ
Yousef, A. et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. npj Precis. Oncol. 8, 27 (2024).
Google ScholarÂ
Osterlund, E. et al. KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts. BJC Rep. 3, 72 (2025).
Google ScholarÂ
Ricciuti, B. et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann. Oncol. 33, 1029–1040 (2022).
Google ScholarÂ
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M. & Kraut, N. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 12, 924–937 (2022).
Google ScholarÂ
Lokhandwala, J., Smalley, T. B. & Tran, T. H. Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance. Front. Oncol. 14, 1394702 (2024).
Google ScholarÂ
Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 6, 386 (2021).
Google ScholarÂ
Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021).
Google ScholarÂ
Pant, S. et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation. J. Clin. Oncol. 41, 425082–425082 (2023).
Google ScholarÂ
Oya, Y., Imaizumi, K. & Mitsudomi, T. The next-generation KRAS inhibitors…what comes after sotorasib and adagrasib?. Lung Cancer 194, 107886 (2024).
Google ScholarÂ
Zhou, Q. et al. Efficacy and safety of KRASG12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study. J. Thorac. Oncol. 19, 1630–1639 (2024).
Google ScholarÂ
Zeissig, M. N. et al. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer 9, 955–967 (2023).
Google ScholarÂ
Norton, C. et al. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw. Open. 8, e2453588 (2025).
Google ScholarÂ
Dayyani, F., Macarulla, T., Johnson, A. & Wainberg, Z. A. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: a systematic literature review. Cancer Treat. Rev. 113, 102502 (2023).
Google ScholarÂ
Durm, G. & Hanna, N. Second-line chemotherapy and beyond for non-small cell lung cancer. Hematol. Oncol. Clin. North Am. 31, 71–81 (2017).
Google ScholarÂ
Imperial, R. et al. Second-line treatment of pancreatic adenocarcinoma: shedding light on new opportunities and key talking points from clinical trials. Clin. Exp. Gastroenterol. 17, 121–134 (2024).
Google ScholarÂ
Wang, K., Leyba, A. & Hsu, R. Addressing the unmet need in NSCLC progression with advances in second-line therapeutics. Explor. Target. Antitumor Ther. 5, 1297–1320 (2024).
Google ScholarÂ
Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. 28, 2171–2182 (2022).
Google ScholarÂ
Pradeep, R. et al. KRAS inhibition in pancreatic ductal adenocarcinoma. J Clin Med. 15, 873 (2026).
Google ScholarÂ
Zhou, C. et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell 42, 1286–1300 e1288 (2024).
Google ScholarÂ
Arbour, K. C. et al. Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. Cancer Res. 85, abstr. CT019 (2025).
Park, W. et al. Setidegrasib in advanced non–small-cell lung cancer and pancreatic cancer. N. Engl. J. Med. 394, 1409–1420 (2026).
Google ScholarÂ
Kumar, V. et al. An overview of KRAS G12D inhibitors: expanding the therapeutic frontier of KRAS in targeting KRAS G12D using diverse therapeutic modalities. Eur. J. Med. Chem. 305, 118555 (2026).
Google ScholarÂ
Yan, F. et al. GFH375 (VS-7375): an oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy. Cancer Res. 84, abstr.3318 (2024).
Google ScholarÂ
Ai, X. et al. A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. J. Clin. Oncol. 43, abstr. 3013 (2025).
Wolpin, B. M. et al. Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer. N. Engl. J. Med. 394, 1790–1802 (2026).
Google ScholarÂ
O’Reilly, E. M. et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2605555 (2026).
Pachter, J. A. et al. GFH375 (VS-7375): an oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models. Cancer Res. 85, abstr. 4394 (2025).
Coma, S. et al. VS-7375: an oral, selective KRAS G12D dual ON/OFF inhibitor with potent anti-tumor activity as a single agent and in combination with other agents. Cancer Res. 86, abstr. 7100 (2026).
Brandon, L. et al. VS-7375, a non-covalent dual ON/OFF KRASG12D inhibitor, displays superior activity to ON-only KRASG12D inhibitors in preclinical models of pancreatic cancer. Cancer Res. 86, abstr. LB197 (2026).
Majem, M. et al. LBA1: first-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. J. Thorac. Oncol. 20, S1 (2025).
Google ScholarÂ
Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272–1281 (2023).
Google ScholarÂ
Cui, J. et al. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. Signal Transduct. Target. Ther. 9, 248 (2024).
Google ScholarÂ
Xiong, A. et al. 915O KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: a phase I trial. Ann. Oncol. 36, S558–S559 (2025).
Google ScholarÂ
Spira, A. I. et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J. Clin. Oncol. 43, 724–724 (2025).
Google ScholarÂ
Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382–2393 (2021).
Google ScholarÂ
Amodio, V. et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10, 1129–1139 (2020).
Google ScholarÂ
Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).
Google ScholarÂ
Zhang, Y. et al. Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer Cell 44, 77–93.e8 (2026).
Google ScholarÂ
Yaeger, R. et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. Cancer Discov. 14, 982–993 (2024).
Google ScholarÂ
Kuboki, Y. et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat. Med. 30, 265–270 (2024).
Google ScholarÂ
Garrido-Laguna, I. et al. LB-B008, A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring allosteric KRAS inhibitor, in patients with solid tumors with KRASG12D mutation. Mol. Cancer Ther. 24 abstr. LB-B008 (2025).
Cook, J. H. et al. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat. Commun. 12, 1808 (2021).
Google ScholarÂ
Zhang, L. et al. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. Cancer 123, 2927–2935 (2017).
Google ScholarÂ
Ying, H. Q. et al. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy. Sci. Rep. 5, 11348 (2015).
Google ScholarÂ
Zhang, D. et al. The association between BIM deletion polymorphism and treatment efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC. J. Clin. Oncol. 40, e21055 (2022).
Google ScholarÂ
Murimwa, G. Z. et al. SMAD4 deficiency promotes pancreatic cancer progression and confers susceptibility to TGFβ inhibition. Cancer Res. 85, 2987–2996 (2025).
Google ScholarÂ
Yao, H. et al. New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas. Biochim. Biophys. Acta Rev. Cancer 1879, 189220 (2024).
Google ScholarÂ
Arbour, K. C. et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin. Cancer Res. 24, 334–340 (2018).
Google ScholarÂ
Skoulidis, F. et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822–835 (2018).
Google ScholarÂ
